Endocannabinoid system and drug addiction: New insights from mutant mice approaches

Current Opinion in Neurobiology

Volumn 23, Issue 4, 2013, Pages 480-486

  Maldonado, Rafael ^a   Robledo, Patricia ^a,b   Berrendero, Fernando ^a  

^a University of Pompeu Fabra   (Spain)

^b HOSPITAL DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; ACYLGLYCEROL LIPASE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; ENDOCANNABINOID; FATTY ACID AMIDASE;

ALCOHOL ABUSE; COCAINE DEPENDENCE; DISEASE SEVERITY; DNA MODIFICATION; DOPAMINERGIC SYSTEM; DRUG ABUSE; DRUG DEPENDENCE; GABAERGIC TRANSMISSION; GENE DELETION; GENE DISRUPTION; MORPHINE ADDICTION; MOUSE MUTANT; NONHUMAN; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TOBACCO DEPENDENCE; VENTRAL TEGMENTUM; WITHDRAWAL SYNDROME;

EID: 84881027576     PISSN: 09594388     EISSN: 18736882     Source Type: Journal    
DOI: 10.1016/j.conb.2013.02.004     Document Type: Review

References (46)

1. Serrano A., Parsons L.H. Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors. Pharmacol Ther 2011, 132:215-241.
2. Mechoulam R., Parker L. The endocannabinoid system and brain. Annu Rev Psychol 2012, 64:6.1-6.27.
3. Van Sickle M.D., Duncan M., Kingsley P.J., Mouihate A., Urbani P., Mackie K., Stella N., Makriyannis A., Piomelli D., Davison J.S., et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005, 310:329-332.
4. Castillo P.E., Younts T.J., Chávez A.E., Hashimotodani Y. Endocannabinoid signaling and synaptic function. Neuron 2012, 76:70-81.
5. Lucchicchi A., Pistis M. Anandamide and 2-arachidonoylglycerol: pharmacological properties, functional features, and emerging specificities of the two major endocannabinoids. Mol Neurobiol 2012, 46:374-392.
6. Clapper J.R., Mangieri R.A., Piomelli D. The endocannabinoid system as a target for the treatment of cannabis dependence. Neuropharmacology 2009, 56(Suppl. 1):235-243.
7. Maldonado R., Valverde O., Berrendero F. Involvement of the endocannabinoid system in drug addiction. Trends Neurosci 2006, 29:225-232.
8. Castañé A., Valjent E., Ledent C., Parmentier M., Maldonado R., Valverde O. Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. Neuropharmacology 2002, 43:857-867.
9. Merritt L.L., Martin B.R., Walters C., Lichtman A.H., Damaj M.I. The endogenous cannabinoid system modulates nicotine reward and dependence. J Pharmacol Exp Ther 2008, 326:483-492.
10. Shoaib M. The cannabinoid antagonist AM251 attenuates nicotine self-administration and nicotine-seeking behaviour in rats. Neuropharmacology 2008, 54:438-444.
11. Cossu G., Ledent C., Fattore L., Imperato A., Böhme G.A., Parmentier M., Fratta W. Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behav Brain Res 2001, 118:61-65.
12. Houchi H., Babovic D., Pierrefiche O., Ledent C., Daoust M., Naassila M. CB1 receptor knockout mice display reduced ethanol-induced conditioned place preference and increased striatal dopamine D2 receptors. Neuropsychopharmacology 2005, 30:339-349.
13. Thanos P.K., Dimitrakakis E.S., Rice O., Gifford A., Volkow N.D. Ethanol self-administration and ethanol conditioned place preference are reduced in mice lacking cannabinoid CB1 receptors. Behav Brain Res 2005, 164:206-213.
14. Hungund B.L., Szakall I., Adam A., Basavarajappa B.S., Vadasz C. Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens. J Neurochem 2003, 84:698-704.
15. Vinod K.Y., Sanguino E., Yalamanchili R., Manzanares J., Hungund B.L. Manipulation of fatty acid amide hydrolase functional activity alters sensitivity and dependence to ethanol. J Neurochem 2008, 104:233-243.
16. Pava M.J., Woodward J.J. A review of the interactions between alcohol and the endocannabinoid system: implications for alcohol dependence and future directions for research. Alcohol 2012, 46:185-204.
17. Racz I., Bilkei-Gorzo A., Toth Z.E., Michel K., Palkovits M., Zimmer A. A critical role for the cannabinoid CB1 receptors in alcohol dependence and stress-stimulated ethanol drinking. J Neurosci 2003, 23:2453-2458.
18. Martin M., Ledent C., Parmentier M., Maldonado R., Valverde O. Cocaine, but not morphine, induces conditioned place preference and sensitization to locomotor responses in CB1 knockout mice. Eur J Neurosci 2000, 12:4038-4046.
19. Rice O.V., Gordon N., Gifford A.N. Conditioned place preference to morphine in cannabinoid CB1 receptor knockout mice. Brain Res 2002, 945:135-138.
20. Ledent C., Valverde O., Cossu G., Petitet F., Aubert J.F., Beslot F., Böhme G.A., Imperato A., Pedrazzini T., Roques B.P., et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999, 283:401-404.
21. Mascia M.S., Obinu M.C., Ledent C., Parmentier M., Böhme G.A., Imperato A., Fratta W. Lack of morphine-induced dopamine release in the nucleus accumbens of cannabinoid CB(1) receptor knockout mice. Eur J Pharmacol 1999, 383:R1-R2.
22. Caillé S., Parsons L.H. SR 141716A reduces the reinforcing properties of heroin but not heroin-induced increases in nucleus accumbens dopamine in rats. Eur J Neurosci 2003, 18:3145-3149.
23. Soria G., Mendizábal V., Touriño C., Robledo P., Ledent C., Parmentier M., Maldonado R., Valverde O. Lack of CB1 cannabinoid receptor impairs cocaine self-administration. Neuropsychopharmacology 2005, 30:1670-1680.
24. Li X., Hoffman A.F., Peng X.Q., Lupica C.R., Gardner E.L., Xi Z.X. Attenuation of basal and cocaine-enhanced locomotion and nucleus accumbens dopamine in cannabinoid CB1-receptor-knockout mice. Psychopharmacology (Berl) 2009, 204:1-11.
25. Touriño C., Ledent C., Maldonado R., Valverde O. CB1 cannabinoid receptor modulates 3,4-methylenedioxymethamphetamine acute responses and reinforcement. Biol Psychiatry 2008, 63:1030-1038.
26. Bellocchio L., Lafenêtre P., Cannich A., Cota D., Puente N., Grandes P., Chaouloff F., Piazza P.V., Marsicano G. Biomodal control of stimulated food intake by the endocannabinoid system. Nat Neurosci 2010, 13:281-283.
27. Ishiguro H., Iwasaki S., Teasenfitz L., Higuchi S., Horiuchi Y., Saito T., Arinami T., Onaivi E.S. Involvement of cannabinoid CB2 receptor in alcohol preference in mice and alcoholism in humans. Pharmacogenomics J 2007, 7:380-385.
28. Xi Z.X., Peng X.Q., Li X., Song R., Zhang H.Y., Liu Q.R., Yang H.J., Bi G.H., Li J., Gardner E.L. Brain cannabinoid CB2 receptors modulate cocaine's actions in mice. Nat Neurosci 2011, 14:1160-1166.
29. Aracil-Fernández A., Trigo J.M., García-Gutiérrez M.S., Ortega-Álvaro A., Ternianov A., Navarro D., Robledo P., Berbel P., Maldonado R., Manzanares J. Decreased cocaine motor sensitization and self-administration in mice overexpressing cannabinoid CB2 receptors. Neuropsychopharmacology 2012, 37:1749-1763.
30. Gamaleddin I., Zvonok A., Makriyannis A., Goldberg S.R., Le Foll B. Effects of a selective cannabinoid CB2 agonist and antagonist on intravenous nicotine self administration and reinstatement of nicotine seeking. PLoS ONE 2012, 7:e29900.
31. Schlosburg J.E., Blankman J.L., Long J.Z., Nomura D.K., Pan B., Kinsey S.G., Nuguyen P., Ramesh D., Booker L., Burston J.J., et al. Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat Neurosci 2010, 13:1113-1119.
32. Forget B., Coen K.M., Le Foll B. Inhibition of fatty acid amide hydrolase reduces reinstatement of nicotine seeking but not break point for nicotine self-administration-comparison with CB(1) receptor blockade. Psychopharmacology (Berl) 2009, 205:613-624.
33. Cippitelli A., Astarita G., Duranti A., Caprioli G., Ubaldi M., Stopponi S., Kallupi M., Sagratini G., Rodrìguez de Fonseca F., Piomelli D., Ciccocioppo R. Endocannabinoid regulation of acute and protracted nicotine withdrawal: effect of FAAH inhibition. PLoS ONE 2011, 6:128-142.
34. Blednov Y.A., Cravatt B.F., Boehm S.L., Walker D., Harris R.A. Role of endocannabinoids in alcohol consumption and intoxication: studies of mice lacking fatty acid amide hydrolase. Neuropsychopharmacology 2007, 32:1570-1582.
35. Basavarajappa B.S., Yalamanchili R., Cravatt B.F., Cooper T.B., Hungund B.L. Increased ethanol consumption and preference and decreased ethanol sensitivity in female FAAH knockout mice. Neuropharmacology 2006, 50:834-844.
36. Shahidi S., Hasanein P. Behavioral effects of fatty acid amide hydrolase inhibition on morphine withdrawal symptoms. Brain Res Bull 2011, 86:118-122.
37. Ramesh D., Ross G.R., Schlosburg J.E., Owens R.A., Abdullah R.A., Kinsey S.G., Long J.Z., Nomura D.K., Sim-Selley L.J., Cravatt B.F., et al. Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice. J Pharmacol Exp Ther 2011, 339:173-185.
38. Adamczyk P., McCreary A.C., Przegalinski E., Mierzejewski P., Bienkowski P., Filip M. The effects of fatty acid amide hydrolase inhibitors on maintenance of cocaine and food self-administration and on reinstatement of cocaine-seeking and food-taking behavior in rats. J Physiol Pharmacol 2009, 60:119-125.
39. Justinová Z., Solinas M., Tanda G., Redhi G.H., Goldberg S.R. The endogenous cannabinoid anandamide and its synthetic analog R(+)-methanandamide are intravenously self-administered by squirrel monkeys. J Neurosci 2005, 25:5645-5650.
40. Justinová Z., Mangieri R.A., Bortolato M., Chefer S.I., Mukhin A.G., Clapper J.R., King A.R., Redhi G.H., Yasar S., Piomelli D., Goldberg S.R. Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates. Biol Psychiatry 2008, 64:930-937.
41. Busquets-Garcia A., Puighermanal E., Pastor A., de la Torre R., Maldonado R., Ozaita A. Differential role of anadamide and 2-arachidonoylglycerol in memory and anxiety-like responses. Biol Psychiatry 2011, 70:479-486.
42. Long J.Z., Li W., Booker L., Burston J.J., Kinsey S.G., Schlosburg J.E., Pavón F.J., Serrano A.M., Selley D.E., Parsons L.H., et al. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 2009, 5:37-44.
43. Justinová Z., Yasar S., Redhi G.H., Goldberg S.R. The endogenous cannabinoid 2-arachidonoylglycerol is intravenously self-administered by squirrel monkeys. J Neurosci 2011, 31:7043-7048.
44. Jung K., Jason C., Fu J., D'Agostino G., Guijarro A., Thongkham D., Avanesian A., Astarita G., DiPatrizio N.V., Frontini A., et al. 2-Arachidonoylglycerol signaling in forebrain regulates systemic energy metabolism. Cell Metab 2012, 15:299-310.
45. Katona I., Urbán G.M., Wallace M., Ledent C., Jung K.M., Piomelli D., Mackie K., Freund T.F. Molecular composition of the endocannabinoid system at glutamatergic synapses. J Neurosci 2006, 26:5628-5637.
46. Kenny P.J. 'Macrophage' cannabinoid receptor goes up in smoke. Nat Neurosci 2011, 9:1100-1102.